PMID- 21855232
OWN - NLM
STAT- MEDLINE
DCOM- 20120209
LR  - 20181201
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
VI  - 207
IP  - 9
DP  - 2011 Sep 15
TI  - ALK-positive extramedullary plasmacytoma with expression of the CLTC-ALK fusion 
      transcript.
PG  - 587-91
LID - 10.1016/j.prp.2011.07.001 [doi]
AB  - Anaplastic lymphoma kinase (ALK)-positive non-Hodgkin lymphoma (NHL) was long 
      thought to be a disease occurring uniquely in T or null-cell lymphomas. More 
      recently, however, a small number of B-lineage lymphomas have been reported to 
      express ALK fusion genes. These tumors often exhibit a plasmablastic morphology, 
      a finding which prompted our interest in looking for ALK fusions in plasma cell 
      neoplasms. We studied 46 cases of extramedullary plasmacytoma by immunostaining 
      with anti-ALK antibody and fluorescence in situ hybridization (FISH) analysis 
      using an ALK break-apart probe and found one case to be ALK protein-positive and 
      demonstrated the disruption of the ALK gene in this case. Immunohistochemistry 
      showed that the tumor cells were strongly positive for CD138, VS38c, and 
      epithelial membrane antigen, but lacked expression of CD20, CD79a, CD45, and 
      CD30. Both RT-PCR and genomic DNA-PCR confirmed the CLTC-ALK fusion. This finding 
      expands the lists of the ALK-positive tumors, and ALK-positive extramedullary 
      plasmacytoma may benefit from the treatment of ALK inhibitor in the future.
CI  - Copyright (c) 2011 Elsevier GmbH. All rights reserved.
FAU - Wang, Wei-ya
AU  - Wang WY
AD  - Department of Pathology, West China Hospital of Sichuan University, Chengdu, 
      China.
FAU - Gu, Ling
AU  - Gu L
FAU - Liu, Wei-ping
AU  - Liu WP
FAU - Li, Gan-di
AU  - Li GD
FAU - Liu, Hua-jun
AU  - Liu HJ
FAU - Ma, Zhi-gui
AU  - Ma ZG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110819
PL  - Germany
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (oncoprotein CLTCL-ALK)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Anaplastic Lymphoma Kinase
MH  - Biomarkers, Tumor/metabolism
MH  - DNA, Neoplasm/analysis
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Magnetic Resonance Imaging
MH  - Oncogene Proteins, Fusion/*genetics/*metabolism
MH  - Plasmacytoma/*enzymology/pathology
MH  - Receptor Protein-Tyrosine Kinases/*genetics/*metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2011/08/23 06:00
MHDA- 2012/02/10 06:00
CRDT- 2011/08/23 06:00
PHST- 2011/02/21 00:00 [received]
PHST- 2011/06/19 00:00 [revised]
PHST- 2011/07/07 00:00 [accepted]
PHST- 2011/08/23 06:00 [entrez]
PHST- 2011/08/23 06:00 [pubmed]
PHST- 2012/02/10 06:00 [medline]
AID - S0344-0338(11)00149-X [pii]
AID - 10.1016/j.prp.2011.07.001 [doi]
PST - ppublish
SO  - Pathol Res Pract. 2011 Sep 15;207(9):587-91. doi: 10.1016/j.prp.2011.07.001. Epub 
      2011 Aug 19.